Core-shell polymer nanoparticle

Patent metadata

Field	Value
Publication number	US-11766409-B2
Application number	US-201917059770-A
Country	US
Kind code	B2
Filing date	May 31, 2019
Priority date	May 31, 2018
Publication date	Sep 26, 2023
Grant date	Sep 26, 2023

Abstract

A method of forming a core-shell polymer nanoparticle encapsulating an active agent is disclosed, including the use of a multi-solvent system in which to dissolve the active agent and a polymer prior to their precipitation using an antisolvent. The preferred use of an organic solvent system comprising two or more organic solvents allows for a high degree of control, as compared with the use of a single solvent, and enables the active agent to be precipitated more or less simultaneously with, or just prior to, the polymer.

First claim

The invention claimed is:

1. A method of forming a core-shell polymer nanoparticle comprising an active agent including the steps of:
(a) dissolving a polymer and an active agent in a solvent system, the solvent system comprising at least two organic solvents, to thereby form an active solution; wherein the w/w ratio of the active agent to the polymer (being the total polymer content) in the active solution is between 5:1 to 1:5; wherein the solvents forming the solvent system are at least two of DMSO, DMF and ethanol; and
wherein when DMSO is present, it forms between 20% to 60% (v/v) of the solvent system;
wherein when DMF is present, it forms between 20% to 45% (v/v) of the solvent system; and
wherein when ethanol is present, it forms between 10% to 50% (v/v) of the solvent system;

(b) mixing the active solution with at least one antisolvent to precipitate the active agent and the polymer; wherein the antisolvent is a polar solvent, and comprises an aqueous solution; wherein the ratio of antisolvent to solvent system is between about 5:1 to about 50:1; and
(c) allowing the precipitated polymer and active agent to form a core-shell polymer nanoparticle comprising the active agent.

2. The method of claim 1 wherein the polymer is a natural or synthetic biocompatible polymer.

3. The method of claim 2 wherein the natural polymer is a resin.

4. The method of claim 1 wherein the polymer is a block copolymer.

5. The method of claim 4 wherein the polymer is an amphiphilic block copolymer.

6. The method of claim 1 wherein the polymer is at least two polymers.

7. The method of claim 1 wherein the active agent is selected from an anti-infective, antimalarial, antiviral, antibiotic, antifungal, antioxidant, antiprotozoal, antineoplastic, cardiovascular agent, antihypertensive, analgesic, anticoagulant, antidepressant, antiarthritic, antipsychotic, neuroprotective, radiologic, respiratory agent, anti-cancer, anti-migraine and antipyretic.

8. The method of claim 6 wherein the active agent is selected from taxol (paclitaxel), taxol derivatives including docetaxel, doxorubicin, bulleyaconitine A, amphotericin B, scutellarin, quercetin, silibinin, oleanolic acid, betulinic acid, honokiol, camptothecin, camptothecin derivatives, curcumin and curcumin derivatives, ibuprofen and ketamine.

9. The method of claim 1 wherein the solvent system comprises at least three organic solvents.

10. The method of claim 1 wherein the majority of the solvent system comprises DMSO and/or DMF.

11. The method of claim 1 wherein the antisolvent is water.

12. The method of claim 1 , wherein when DMF is present, it forms between 25% to 40% (v/v) of the solvent system.

13. The method of claim 1 , wherein when DMSO is present, it forms between 25% to 55% (v/v) of the solvent system.

14. The method of claim 1 , wherein when ethanol is present, it forms between 30% to 50% (v/v) of the solvent system.

Assignees

• Univ Queensland

Inventors

• Zhao Chunxia
• Liu Yun

Classifications

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• B82Y40/00

  Manufacture or treatment of nanostructures · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K31/439

  the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title